摘要
４０例成人急性早幼粒细胞白血病经全反式维甲酸（ＡＴＲＡ）诱导分化达完全缓解（ＣＲ）后，１４例进行化疗与ＡＴＲＡ交替维持治疗，１１例接受异基因骨髓移植（ａｌｌｏ－ＢＭＴ），１５例接受平均６．５月的化疗即终止治疗。随访结果显示，ＢＭＴ组复发率最低（９．１％），维持组次之（４６．２％），终止组最高（８０．０％）。３组３年存活率依次为７０．１％，５１．４％和１８．５％。３年持续完全缓解（ＣＣＲ）率维持组与终止组分别为５０．０％和１３．０％。再次证实强化疗及骨髓抑制性维持治疗是十分必要的，应尽早进行。应用逆转录－多聚酶联反应技术监测ＰＭＬ－ＲＡＲα融合ｍＲＮＡ，１１例转阴者中１０例ＣＣＲ，１例复发，提示阴转率与转归有较好相关。
orty acute promyelocytic leukemia (APL) patientstreated with all-trans retinoic acid (ATRA) for induc-tion entered different post-remission therapy protocols.The patients were divided into three groups : ① 14 caseswere treated with cytotoxic chernotherapy and ATRAalternatively up to three years; ②11 cases received allo-bone marrow transplantation (BMT) ;③15 cases refusedto continue antileukemic therapy after several courses ofconsolidation.The relapse rates for group 1, 2 and 3were 46. 2%, 9.1% and 80% , and the 3-year survivalrates were 70% , 51. 4% and 18. 5% , respectively.The above results suggested that intensive chemotherapyor myelosuppressive maintenance treatment was neces-sary and should be used as early as possible. RAR-α/PML fusion mRNA were detected by RT-PCR assay in12 patients. Ten of the 11 patients whose test becamenegative remained in continued remission.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
1995年第5期247-249,共3页
Chinese Journal of Hematology
关键词
全反式维甲酸
白血病
髓细胞性
药物疗法
All-trans retinoic acid Post-remissiontherapy Acute promyelocyticleukemia
